Search Within

Jia Luo

Formats
  1. Journal Article (16)
  2. Meeting Abstract (8)
  3. Review (2)
  4. Research Letter (1)
Groups
  1. Hematology-Oncology Fellows (27)
  2. Department of Medicine (25)
  3. Solid Tumor Oncology Division (25)
  4. Thoracic Oncology (25)
  5. Radiology, Department of (12)
  6. Weinberg Fellows (12)

More Groups

People
  1. Matthew Hellmann (19)
  2. Hira Rizvi (18)
  3. Mark Kris (13)
  4. Andrew Plodkowski (10)
  5. Jacklynn Egger (10)
  6. Adam Schoenfeld (7)

More People

Years
  1. 2024 (2)
  2. 2022 (3)
  3. 2021 (8)
  4. 2020 (14)
Publications
  1. Journal of Clinical Oncology (7)
  2. Cancer Discovery (3)
  3. Clinical Cancer Research (3)
  4. Annals of Oncology (2)
  5. JCO Precision Oncology (2)
  6. Journal for ImmunoTherapy of Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (10)
  2. American Association for Cancer Research (6)
  3. Biomed Central Ltd (2)
  4. Elsevier Inc. (2)
  5. Nature Publishing Group (2)
  6. Oxford University Press (2)

More Publishers

Results (27)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • COVID-19 in patients with lung cancer
    Journal Article

    Luo, J.; Rizvi, H.; Preeshagul, I. R.; Egger, J. V.; Hoyos, D.; Bandlamudi, C.; McCarthy, C. G.; Falcon, C. J.; Schoenfeld, A. J.; Arbour, K. C.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • CNS metastases in patients with MET exon 14-altered lung cancers and outcomes with crizotinib
    Journal Article

    Offin, M.; Luo, J.; Guo, R.; Lyo, J. K.; Falcon, C.; Dienstag, J.; Wilkins, O.; Chang, J.; Rudin, C. M.; Riely, G.; more...
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save
  • Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers
    Journal Article

    Luo, J.; Rizvi, H.; Egger, J. V.; Preeshagul, I. R.; Wolchok, J. D.; Hellmann, M. D.
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • MET-dependent solid tumours — Molecular diagnosis and targeted therapy
    Review

    Guo, R.; Luo, J.; Chang, J.; Rekhtman, N.; Arcila, M.; Drilon, A.
    Nature Reviews Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status
    Journal Article

    Alessi, J. V.; Ricciuti, B.; Jiménez-Aguilar, E.; Hong, F.; Wei, Z.; Nishino, M.; Plodkowski, A. J.; Sawan, P.; Luo, J.; Rizvi, H.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC
    Journal Article

    Hellmann, M. D.; Nabet, B. Y.; Rizvi, H.; Chaudhuri, A. A.; Wells, D. K.; Dunphy, M. P. S.; Chabon, J. J.; Liu, C. L.; Hui, A. B.; Arbour, K. C.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Making checkpoint inhibitors part of treatment of patients with locally advanced lung cancers: The time is now
    Review

    Kris, M. G.; Faivre-Finn, C.; Kordbacheh, T.; Chaft, J.; Luo, J.; Tsao, A.; Swisher, S.
    American Society of Clinical Oncology Educational Book (2020)

    Fulltext@MSK | Save